PL356028A1 - Produkt zawierający inhibitor przetwarzania sygnałów heterotrimerycznego białka G w kombinacji z innym środkiem przeciwrakowym do stosowania terapeutycznego w leczeniu raka - Google Patents

Produkt zawierający inhibitor przetwarzania sygnałów heterotrimerycznego białka G w kombinacji z innym środkiem przeciwrakowym do stosowania terapeutycznego w leczeniu raka

Info

Publication number
PL356028A1
PL356028A1 PL00356028A PL35602800A PL356028A1 PL 356028 A1 PL356028 A1 PL 356028A1 PL 00356028 A PL00356028 A PL 00356028A PL 35602800 A PL35602800 A PL 35602800A PL 356028 A1 PL356028 A1 PL 356028A1
Authority
PL
Poland
Prior art keywords
therapeutic use
cancer
another anti
signals combined
protein signals
Prior art date
Application number
PL00356028A
Other languages
English (en)
Other versions
PL204716B1 (pl
Inventor
Gregoire Prevost
Marie-Odile Lonchampt
Thomas Gordon
Barry Morgan
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9914037A external-priority patent/FR2800616B1/fr
Priority claimed from FR0000104A external-priority patent/FR2803524B1/fr
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Publication of PL356028A1 publication Critical patent/PL356028A1/pl
Publication of PL204716B1 publication Critical patent/PL204716B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL356028A 1999-11-09 2000-11-08 Produkt zawierający inhibitor transdukcji sygnałów heterotrimerycznego białka G w kombinacji z innym środkiem przeciwrakowym do stosowania terapeutycznego w leczeniu raka PL204716B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9914037A FR2800616B1 (fr) 1999-11-09 1999-11-09 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR0000104A FR2803524B1 (fr) 2000-01-06 2000-01-06 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
PCT/FR2000/003098 WO2001034203A1 (fr) 1999-11-09 2000-11-08 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer

Publications (2)

Publication Number Publication Date
PL356028A1 true PL356028A1 (pl) 2004-06-14
PL204716B1 PL204716B1 (pl) 2010-02-26

Family

ID=26212071

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356028A PL204716B1 (pl) 1999-11-09 2000-11-08 Produkt zawierający inhibitor transdukcji sygnałów heterotrimerycznego białka G w kombinacji z innym środkiem przeciwrakowym do stosowania terapeutycznego w leczeniu raka

Country Status (15)

Country Link
US (3) US7034024B1 (pl)
EP (2) EP1430934A1 (pl)
JP (1) JP2003513940A (pl)
AT (1) ATE284224T1 (pl)
AU (1) AU1400401A (pl)
CA (1) CA2390317C (pl)
CZ (1) CZ20021550A3 (pl)
DE (1) DE60016625T2 (pl)
DK (1) DK1233787T3 (pl)
ES (1) ES2234692T3 (pl)
HU (1) HUP0203241A3 (pl)
PL (1) PL204716B1 (pl)
PT (1) PT1233787E (pl)
RU (1) RU2298417C2 (pl)
WO (1) WO2001034203A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
KR100594353B1 (ko) * 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
DE102009033392A1 (de) * 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
EP3590940B1 (en) * 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
CN106317057B (zh) * 2015-07-02 2019-02-01 北京桦冠医药科技有限公司 具有咪唑并吡嗪类衍生物，其制备及其在医药上的应用
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
AU2018260414A1 (en) 2017-04-24 2019-10-17 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof
CN112480122B (zh) * 2020-11-24 2022-03-22 中山大学 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0517353A (ja) * 1991-07-10 1993-01-26 Kanebo Ltd 制癌作用増強剤
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EE03484B1 (et) * 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
BR9814419A (pt) * 1997-12-22 2000-10-10 Schering Corp "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase

Also Published As

Publication number Publication date
HUP0203241A2 (hu) 2003-02-28
DE60016625D1 (de) 2005-01-13
HUP0203241A3 (en) 2006-07-28
DK1233787T3 (da) 2005-08-15
DE60016625T2 (de) 2005-12-22
WO2001034203A1 (fr) 2001-05-17
US20060074078A1 (en) 2006-04-06
CA2390317A1 (fr) 2001-05-17
PT1233787E (pt) 2005-04-29
EP1430934A1 (fr) 2004-06-23
ES2234692T3 (es) 2005-07-01
ATE284224T1 (de) 2004-12-15
RU2002115262A (ru) 2004-01-27
JP2003513940A (ja) 2003-04-15
PL204716B1 (pl) 2010-02-26
EP1233787B8 (fr) 2005-05-18
RU2298417C2 (ru) 2007-05-10
CA2390317C (fr) 2010-03-23
AU1400401A (en) 2001-06-06
EP1233787B1 (fr) 2004-12-08
EP1233787A1 (fr) 2002-08-28
US7034024B1 (en) 2006-04-25
US20090270341A1 (en) 2009-10-29
CZ20021550A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
AU1400401A (en) Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2004110490A3 (en) Use of vegf inhibitors for tumor regression
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
WO2003080582A3 (de) Fredericamycin-derivate
WO2000044774A3 (en) Inhibition of stat3 signal transduction for human cancer therapy
MX9803792A (es) Inhibidor de proteina cinasa c.
MX9705273A (es) Inhibidores de prenil transferasas.
GEP20084317B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001056552A3 (en) Farnesyl protein transferase inhibitors for treating breast cancer
MX9707431A (es) Inhibidores de la proteina cinasa c.
HUP9803018A3 (en) Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
EP1510221A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
HU905854D0 (en) New peptidase and isomerase inhibitors
WO1997015555A3 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
WO2001022954A3 (de) Indolyl-3-glyoxylsäurederivate als antitumormittel
EA200501019A1 (ru) Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
GB0002336D0 (en) Medicaments
MXPA04003365A (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina.
HUP0302942A3 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors, their use and pharmaceutical compositions containing them
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
WO2002072021A3 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
MXPA03001226A (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados.
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20111108